(Bloomberg) -- The summer IPO drought in Hong Kong is coming to an end.
Shanghai Henlius Biotech Inc., a unit of billionaire Guo Guangchang's Fosun group, started gauging investor demand Monday for a planned initial public offering, according to terms of the deal obtained by Bloomberg. The offering could raise at least $600 million, people with knowledge of the matter have said.
While summer is typically quiet for first-time share sales in Hong Kong as bankers and investors go on holidays, the city's ongoing protests and an escalating trade war between China and the U.S. have hurt investor sentiment. No major listing has completed in the financial hub since mid-July after Jinshang Bank Co. raised $474 million, according to data compiled by Bloomberg. Anheuser-Busch InBev NV stalled a listing of its Asian subsidiary last month.
Companies have raised $1.54 billion via IPOs in Hong Kong since the beginning of July. That compares to $11.5 billion for the same period last year, which had the busiest summer on record with listings of China Tower Corp. and Xiaomi Corp.
Henlius, an unprofitable biopharmaceutical firm, plans to use the IPO proceeds to fund clinical trials and for general corporate purposes, the terms show. One of its products that treats lymphoma has received approval from China's National Medical Products Administration for commercial sales in May, according to a preliminary prospectus.
China International Capital Corp., Bank of America Corp., CMB International Capital Ltd., Fosun Hani Securities and Citigroup Inc. are joint sponsors, the prospectus shows.
Read: Alibaba-Backed AI Startup Sales Tripling Paves Route to IPO (1)
--With assistance from Joyce Koh.
To contact the reporter on this story: Crystal Tse in Hong Kong at ctse44@bloomberg.net
To contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, Katrina Nicholas
©2019 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
